Complement pathway activity in the killing of Pentatrichomonas hominis was investigated in this study. At 105 organisms per ml, P. hominis was completely killed by the presence of 1% normal human serum. In contrast, no killing effect on P. hominis was observed when specific antibodies were absorbed or when the complement was destroyed. Moreover, Mg2"-ethylene glycol-bis-(D-aminoethyl ether)-N,N,N',N'-tetraacetic acid-treated serum had no killing effect on P. hominis, while serum heated at 50°C or treated with zymosan killed P. hominis as well as did normal human serum. Further study using gel filtration (Sephacryl S-300) and affinity chromatography (protein A) revealed that immunoglobulin M (IgM; 20 ,ug/ml) alone was responsible for the complement activation in the killing of P. hominis, but both IgA (24 ,Lg/ml) and IgG (180 ,ug/ml) had no effect on complement-mediated lysis. On the other hand, IgG at 1,260 ,ug/ml completely inhibited complement-mediated killing by IgM, suggesting that a blocking factor is present in IgG. The results of this study indicate that a mechanism of IgM-dependent classical complement pathway activation contributes to the killing effect of normal human serum on P. hominis.
Pentatrichomonas hominis inhabits the large intestines of humans and many other species of mammals. In lessdeveloped parts of the world, this organism is commonly found in diarrheal stool and has been associated with abdominal discomfort (10) , although it has not been shown to be pathogenic for humans. There is also no convincing evidence that P. hominis can cause disease in immunocompromised patients, but there could be a potential problem. In fact, other intestinal protozoa, such as Cryptosporidium sp. and Isospora sp. were considered innocuous until the acquired immune deficiency syndrome appeared. Moreover, several reports have aroused suspicion that this commensal organism could be found in areas other than the gastrointestinal tract (13, 24, 26) . A trichomonad species which could have been P. hominis was found in the cerebrospinal fluid of a patient with esophageal carcinoma, and spread from the gut was considered possible (13) . We also reported a case of P. hominis infection in a lymphoma patient with severe diarrhea (23) . With the increased incidence of opportunistic infections in immunocompromised and immunodeficient hosts, the pathogenesis of P. hominis infection could become an important subject for investigation. Little work on the immune response to P. hominis has been undertaken. To elucidate the role of humoral immunity in the defense mechanisms against P. hominis, complement pathway activity in the killing of this organism was intensively investigated in this study.
MATERIALS AND METHODS
Organisms. Axenically cultivated P. hominis (NDMC), originally isolated from a lymphoma patient in our laboratory (23) , was maintained in a modified medium identical to the TYI-S-33 medium of Diamond et al. (4) , with the exception that 0.5% Panmede was added. Two additional strains, obtained from the American Type Culture Collection, were ATCC 30000 and ATCC 30098. Other organisms, including bacteria used for serum absorption, were Trichomonas vag-* Corresponding author.
inalis, Giardia lamblia, Salmonella enteritidis, and Escherichia coli.
Counting of protozoa. The number of flagellates per culture was determined with a Coulter counter (model D industrial; Coulter Electronics, Inc., Hialeah, Fla.) with a 70-,um aperture tube.
Sera. Venous blood from 24 healthy donors who had no recent history of diarrhea or medication within the past 6 months was allowed to clot at room temperature and then centrifuged at 400 x g. C-reactive protein and rheumatoid factor were determined with a nephelometer (Auto ICS; Beckman Instruments, Inc., Fullerton, Calif.), and only test-negative sera were included in this study. Because no cysts are formed, P. hominis infection in healthy donors has been ruled out by the absence of trophozoites in six consecutive stool examinations. Serum from each donor was tested for the killing effect on P. hominis individually. These normal human sera were also pooled and stored at -70°C in 1-ml aliquots. Sera from premature (n = 6) and newborn (n = 7) infants were obtained through the courtesy of K. D. Yang, Department of Pediatrics, Tri-Service General Hospital, National Defense Medical Center, Taipei, Taiwan. Heat inactivation to abolish serum complement activity was performed at 56°C for 30 min. Specific antibodies were removed by absorption with homologous organisms at 5 x 108 flagellates per ml of serum at 4°C for 6 h or at 1010 bacteria per ml of serum at 4°C for 1 h to produce various absorbed sera. Before use, all sera, both treated and untreated, were assayed for antibody reactive to P. hominis by means of agglutination and an indirect immunofluorescence assay as described below. To study the activity of the classical complement pathway (CCP), the serum was depleted of the alternative complement pathway (ACP) by treatment with zymosan A (4 mg/ml of serum; Sigma Chemical Co., St. Louis, Mo.) (1, 18) or depleted of factor B by heat treatment at 50°C for 20 min (2). To deplete CCP activity while leaving the ACP intact, chelation of Ca2" in normal human serum and P. hominis-absorbed serum was performed by addition of 10 mM ethylene glycol-bis-(P-aminoethyl ether)-N,N,N', N'-tetraacetic acid (EGTA; Sigma) containing 1 mM MgCl2 to the sera (5 Serum-killing assay. Duplicate reaction mixtures were set up containing 105 P. hominis per ml which were incubated with various serum preparations at 37°C and rotated end over end for 1 h. Percent parasite survival with this procedure was determined by a regrowth assay performed as previously described (8) . The generation time for P. hominis is 4.4 ± 0.4 h (n = 3). In brief, 100 ,ul of each incubation sample was added in duplicate to 10 ml of freshly prepared TYI-S-33 medium in screw-cap culture tubes (16 by 125 mm). After 48 h of incubation, the concentration of parasites in each culture tube was determined by counting in a Coulter counter. The initial number of viable parasites was then obtained by extrapolation from the standard reference growth curve by using the total number counted at 48 h. The establishment of this assay was based on the fact that the growth of the remaining viable parasites was not inhibited, which was confirmed by prolonged culture and observation for up to 2 weeks. Finally, the percentage of trophozoites surviving the serum treatment was calculated by the following formula: Viability index = number of viable parasites following serum treatment as determined from a standard reference growth curve/total number of parasites incubated with each serum preparation.
RESULTS
Effect of normal human serum on P. hominis killing. The basic experiments on the serum killing of three strains of P. hominis were performed with different serum concentrations (0.1, 1, and 5%) and at three reaction time intervals (10, 20, and 30 min). At 105/ml, the organisms were totally lysed by 1% normal human serum during 30 min of incubation. No killing of P. hominis could be seen when the concentration of normal human serum was 0.1%. Therefore, 1% serum was used in this series of experiments. Each of 24 serum samples had the same capacity to kill P. hominis; i.e., P. hominis was completely lysed by each normal human serum at 1%. However, of the premature (n = 6) and newborn (n = 7) sera tested, none was found to have a killing effect on this parasite.
Measurement of serum antibodies against P. hominis.IgM, IgG, and IgA isotypes of serum antibodies were detected in normal human serum by immunofluorescence with heavychain-specific antisera as described above. In each instance, a diffuse pattern of staining was observed. Purified individual immunoglobulin (IgM, IgG, and IgA) reacted by indirect fluorescent-antibody test with P. hominis also revealed the same patterns (data not shown). All 24 sera agglutinated P. hominis. Agglutination tests revealed that heat-inactivated pooled serum had a titer of 256. Following absorption with P. hominis, the titer was reduced to 4. Absorption with other protozoa (G. lamblia, etc.) failed to remove anti-P. hominis antibody from the sera. Hanks balanced salt solution was used as a control, and no spontaneous agglutination was observed.
Killing effects of serum components on P. hominis. Although normal human serum appeared to kill P. hominis, neither P. hominis-absorbed serum nor heat-inactivated serum had such an effect on the parasite. However, the lytic effect on P. hominis was restored when both P. hominisabsorbed serum and heat-inactivated serum were present ( Table 1 ), suggesting that both complement and antibody are responsible for the ability of normal human serum to kill P. hominis.
Effects of various absorbed sera on P. hominis survival. Serum absorbed with individual strains of P. hominis failed to kill either the homologous or heterologous strains of P. hominis ( Table 2 ), suggesting that common antigens exist among these strains of P. hominis. On the other hand, serum absorbed with other species of protozoa (T. vaginalis and G. lamblia) or bacteria (S. enteritidis and E. coli) remained lethal for P. hominis ( Table 2 ), suggesting that these organisms lacked a common surface antigen present in P. hominis.
Effects of immunoglobulin fractions on P. hominis survival. The effects of immunoglobulin fractions on the viability of P. hominis were tested with or without complement. Without complement, immunoglobulin fractions, either individually or in combinations, did not kill P. hominis. With P. hominisabsorbed serum (as the complement source), only the IgM fraction from either individual or pooled sera was capable of killing the parasite (Table 3) . IgM fraction purity was demonstrated by sodium dodecyl sulfate-polyacrylamide gel electrophoretic analysis, which revealed only two single bands with molecular weights of 65,000 (heavy chain) and 23,000 (light chain), respectively (data not shown). IgM purified from myeloma (Jackson Immuno Research Labora- tories Inc., West Grove, Pa.) was used for comparison and was found to be able to activate complement leading to P. hominis lysis. Since IgG and IgA antibodies were able to bind with P. hominis, as shown by immunofluorescence, we attempted to determine whether these two classes of immunoglobulins could interfere with IgM-dependent, complement-mediated lysis of the parasite. IgG at 540 ,ug/ml significantly (P < 0.01) reduced P. hominis killing by normal human serum. At 1,260 ,ug/ml, it completely inhibited the killing activity of normal human serum (Fig. 1) . To determine whether high concentrations of IgG actually inhibited IgM binding, a quantitative indirect immunofluorescence assay was performed. Binding of IgM to P. hominis was inhibited by increased concentrations of IgG (Fig. 2) . These results suggest that a blocking factor is present in IgG. In contrast, IgA did not block the killing activity of normal human serum (data not shown). A complement hemolytic assay was performed to further examine whether the additional IgG fraction could interfere with complement activity in normal human serum. Both complement pathway activities in the hemolytic assay did not change in the presence of additional IgG (data not shown). Complement pathway activity in P. hominis killing.
Whereas C3 was detected by indirect immunofluorescence on parasites reacted with normal human serum, the parasites failed to stain following incubation in P. hominis-absorbed serum (data not shown), providing further evidence that complement-fixing antibodies are necessary for complement activation. Normal human serum treated with Mg2+-EGTA did not kill P. hominis, while ACP-depleted sera killed the organisms as well as did normal human serum. This indicates that CCP activity exclusively contributes to serum killing. The antibody involved in activation of the CCP leading to P. hominis lysis is IgM (Table 4) .
DISCUSSION
While it is recognized that P. hominis inhabits intestines, where it encounters the mucosal immune system, we chose to study the ability of low concentrations of normal human serum to kill this parasite to determine whether complement and antibody participate in the lethal event. Accordingly, a The observation that heat-inactivated serum and P. hominis-absorbed serum failed to kill P. hominis strongly indicated the participation of both complement and antibody in the killing event. We found that chelation of serum with EGTA, which is known to block complement activation by the classical pathway, abrogated the lethal activity of serum. These findings strongly suggest that killing is mediated by activation of the classical pathway via antibody reacting with parasite antigens. This deduction is supported by the deposition of C3 on the parasite and the fact that ACP-depleted serum was capable of killing P. hominis.
Complement activity in the killing of parasitic protozoa has been investigated intensively. Leishmania donovani promastigotes (17) , Toxoplasma gondii (22), and G. lamblia (7) were killed by normal human serum through CCP activation, while Trichomonas vaginalis (6), Entamoeba histolytica (11, 16) , and Naegleria fowleri (9, 27) activated complement via the alternative pathway. More recently, it has been emphasized that activation of the alternative pathway is important in the lysis of nonpathogenic strains of E. histolytica (20) . P. hominis has never been shown to be pathogenic. However (15) . Further efforts are warranted to determine whether IgG plays a role in the extraintestinal spread of P. hominis.
The question arises as to the origin of these parasitespecific antibodies in the normal human serum used in these studies. Natural antibodies, including IgM, have been shown to be major immunoglobulins involved in the complementmediated lysis of leishmanias (17, 21) . IgM purified from myeloma (Jackson), compared with the IgM fraction purified in this study, had a similar ability to activate complement, leading to P. hominis lysis. Therefore, it is possible that the presence of these IgM antibodies is due to previous inapparent infection or that they are naturally occurring antibodies which result from stimulation by some organisms within the environment.
The fact that P. hominis is killed by complement may have nothing to do with its lack of pathogenicity in humans. However, the ability of low concentrations of serum to kill this parasite not only prevents multiplication of the parasites but also blocks invasion of the submucosa by the parasites in individuals with complement-fixing antibodies. Perhaps this is one of the most effective defense mechanisms to counteract this parasite infection.
